Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licarbazepine for manic episodes of Bipolar I Disorder
NCT00139594Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 4, open-label, single-arm trial of licarbazepine in bipolar I disorder, sponsored by Novartis. Primary endpoints: Rates of adverse events and serious adverse events at 52 weeks, Changes in laboratory values at 52 weeks and 2 more. Started Dec 2004; status: completed.
02
Drugs
licarbazepine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00139594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139594.